{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:53:35Z","timestamp":1789829615698,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Startup Fund for scientific research, Fujian Medical University","award":["2024QH1197"],"award-info":[{"award-number":["2024QH1197"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04642-6","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:59:12Z","timestamp":1760169552000},"page":"3961-3967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Venous thromboembolism events associated with tofacitinib in rheumatoid arthritis patients: a real-world study from FAERS database"],"prefix":"10.1007","volume":"399","author":[{"given":"Jintuo","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"4642_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71:1524\u20131529","journal-title":"Ann Rheum Dis"},{"key":"4642_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70184","volume":"28","author":"M Cao","year":"2025","unstructured":"Cao M, Li C, Li M, Lu K, Wu C, Wang J, Wei C, Zhao J, Wang Q, Tian X et al (2025) Prevalence and incidence of rheumatoid arthritis in urban China: a national population-based study. Int J Rheum Dis 28:e70184","journal-title":"Int J Rheum Dis"},{"key":"4642_CR3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/art.42846","volume":"76","author":"C Charles-Schoeman","year":"2024","unstructured":"Charles-Schoeman C, Fleischmann R, Mysler E, Greenwald M, Ytterberg SR, Koch GG, Bhatt DL, Wang C, Mikuls TR, Chen AS et al (2024) Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients. Arthritis Rheumatol 76:1218\u20131229","journal-title":"Arthritis Rheumatol"},{"key":"4642_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2022.119183","volume":"284","author":"H Chen","year":"2022","unstructured":"Chen H, Sun Y, Xu X, Ye Q (2022) Targeted delivery of methotrexate by modified yeast beta-glucan nanoparticles for rheumatoid arthritis therapy. Carbohydr Polym 284:119183","journal-title":"Carbohydr Polym"},{"key":"4642_CR5","first-page":"809","volume":"23","author":"RJ Desai","year":"2017","unstructured":"Desai RJ, Solomon DH, Jin Y, Liu J, Kim SC (2017) Temporal trends in use of biologic DMARDs for rheumatoid arthritis in the United States: a cohort study of publicly and privately insured patients. J Manag Care Spec Pharm 23:809\u2013814","journal-title":"J Manag Care Spec Pharm"},{"key":"4642_CR6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.40798","volume":"71","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Pawar A, Weinblatt ME, Kim SC (2019) Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study. Arthritis Rheumatol 71:892\u2013900","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4642_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","volume":"61","author":"RJ Desai","year":"2021","unstructured":"Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC (2021) Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford) 61(1):121\u2013130","journal-title":"Rheumatology (Oxford)"},{"key":"4642_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/ard-2022-222824","volume":"82","author":"L Hoisnard","year":"2023","unstructured":"Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E (2023) Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis 82:182\u2013188","journal-title":"Ann Rheum Dis"},{"key":"4642_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/2012.jama.11741","volume":"308","author":"ME Holmqvist","year":"2012","unstructured":"Holmqvist ME, Neovius M, Eriksson J, Mantel A, Wallberg-Jonsson S, Jacobsson LT, Askling J (2012) Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 308:1350\u20131356","journal-title":"JAMA"},{"key":"4642_CR10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/mr\/roac136","volume":"33","author":"JH Ju","year":"2023","unstructured":"Ju JH, Sung YK, Jo JY, Jeon JY, Yoo HJ, Lee EB (2023) Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: a post-marketing surveillance study. Mod Rheumatol 33:1087\u20131096","journal-title":"Mod Rheumatol"},{"key":"4642_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/ard-2022-223715","volume":"82","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B (2023) Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL surveillance. Ann Rheum Dis 82:901\u2013910","journal-title":"Ann Rheum Dis"},{"key":"4642_CR12","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/r9rruc","author":"C Li","year":"2025","unstructured":"Li C, Zong S (2025) A comprehensive analysis of trends and inequalities in rheumatoid arthritis burden among women of childbearing age: insights from the Global Burden of Disease study 2021. Clin Exp Rheumatol. https:\/\/doi.org\/10.55563\/clinexprheumatol\/r9rruc","journal-title":"Clin Exp Rheumatol"},{"key":"4642_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-025-01214-4","author":"MA Lopez-Olivo","year":"2025","unstructured":"Lopez-Olivo MA, Matusevich ARK, Tayar JH, Lu H (2025) Managing rheumatoid arthritis in older adults with cancer. Drugs Aging. https:\/\/doi.org\/10.1007\/s40266-025-01214-4","journal-title":"Drugs Aging"},{"key":"4642_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638444","volume":"12","author":"X Lu","year":"2021","unstructured":"Lu X, Hu R, Peng L, Liu M, Sun Z (2021) Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis. Front Immunol 12:638444","journal-title":"Front Immunol"},{"key":"4642_CR15","first-page":"24","volume":"117","author":"M Obi","year":"2022","unstructured":"Obi M, Aykun N, Otero Pineiro A, McMichael J, Bena J, Xiao H, Holubar S, Lipman J, Steele S, Hull T et al (2022) S92 venous thromboembolism risk in hospitalized tofacitinib-exposed patients: a real-world experience of 533 patients. Official journal of the American College of Gastroenterology | ACG 117:24","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"key":"4642_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70162","volume":"28","author":"Y Ohashi","year":"2025","unstructured":"Ohashi Y, Suzuki M, Sobue Y, Terabe K, Asai S, Imagama S, Takahashi N (2025) Investigation of the risk of frailty progression based on 5-year data in patients with rheumatoid arthritis: a multicenter observational study (T-FLAG). Int J Rheum Dis 28:e70162","journal-title":"Int J Rheum Dis"},{"key":"4642_CR17","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1056\/NEJMc2202778","volume":"386","author":"A Ozdede","year":"2022","unstructured":"Ozdede A, Yazici H (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:1766","journal-title":"N Engl J Med"},{"key":"4642_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/DCR.0000000000003137","volume":"67","author":"TA Russell","year":"2024","unstructured":"Russell TA, Banerjee S, Lipman JM, Holubar SD, Hull TL, Steele SR, Lightner AL (2024) Tofacitinib is associated with increased risk of postoperative venous thromboembolism in patients with ulcerative colitis. Dis Colon Rectum 67:693\u2013699","journal-title":"Dis Colon Rectum"},{"key":"4642_CR19","volume":"17","author":"P Sunkara","year":"2025","unstructured":"Sunkara P, Garikipati NA, Nimmagadda R, Cherukuri AMK, Anne H, Chakilam R, Yadav D (2025) Cardiovascular outcomes of disease-modifying antirheumatic drugs in rheumatoid arthritis: a review of the current evidence. Cureus 17:e82269","journal-title":"Cureus"},{"key":"4642_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18:133\u2013145","journal-title":"Nat Rev Rheumatol"},{"key":"4642_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/1756-185X.12820","volume":"20","author":"P Ungprasert","year":"2017","unstructured":"Ungprasert P, Srivali N, Kittanamongkolchai W (2017) Risk of incident atrial fibrillation in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis 20:434\u2013441","journal-title":"Int J Rheum Dis"},{"key":"4642_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156203","volume":"135","author":"D Yang","year":"2024","unstructured":"Yang D, Lv G, Wu Y, Guo W, Wang Y, Hu J, Li N, Zheng F, Dai Y, Pi Z et al (2024) Licorice-regulated gut-joint axis for alleviating collagen-induced rheumatoid arthritis. Phytomedicine 135:156203","journal-title":"Phytomedicine"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04642-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:58:59Z","timestamp":1772006339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04642-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4642"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04642-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}